Effectiveness of adjunctive antidepressant treatment for bipolar depression.

By G. Sachs, A. Nierenberg, J. Calabrese, L. Marangell, S. Wisniewski, L. Gyulai, E. Friedman, C. Bowden, M. Fossey, M. Ostacher and 10 more. New England Journal of Medicine, 2007

850 citations recorded by the source corpus.

Subfields: Experimental and Cognitive Psychology, Pharmacology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/c224a40d0ffd6471e7b72b38060d169ba1cdec34

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Experimental and Cognitive Psychology

In Pharmacology

In Psychiatry and Mental health

Citations in the corpus

Onset Timing, Thoughts of Self-harm, and Diagnoses in Postpartum Women With Screen-Positive Depression Findings (2013, background): “Treatment of the depressed phase of bipolar disorder with a mood stabilizer and an antidepressant does not confer benefit beyond treatment with a mood stabilizer alone.(60) Given the critical importance of birth as a life event for families, detection and treatment of bipolar disorder among childbea”
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. (2013, background): “For instance, OFC was shown to be more effective than placebo or olanzapine monotherapy (93, 95), but the combination of paroxetine or bupropion with a mood stabilizer was not more effective than a mood stabilizer plus placebo (124).”
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. (2009, methodology): “The STEP-BD study, comparing adjunctive antidepressants (bupropion or paroxetine) plus lithium or divalproex and lithium or divalproex alone, for up to 26 weeks, included 114 patients with BD II (67).”
Interpretable Dynamic Treatment Regimes (2016, background): “…an antidepressant medication to all patients did not lead to a better mean outcome relative to not applying antidepressants to any of the patients (Sachs et al., 2007), the estimated regime indicates that personalizing the use of antidepressants based on SUM-D may improve the overall mean outcome.”
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder (2018, background): “Further, several small crossover trials demonstrated significantly higher response rates to lithium than placebo in patients with acute bipolar depression (245).”
Precision Medicine. (2019, methodology): “They demonstrate the validity of the inference through simulation studies and apply the method to the STEP-BD study data on bipolar disorder (Sachs et al 2007).”
A Randomized Add-on Trial of an N-methyl-d-aspartate Antagonist in Treatment-Resistant Bipolar Depression (2010, result): “Compared with our previous study with ketamine in patients with treatment-resistant major depressive disorder,(34) we found (1) more rapid onset of antidepressant effects (40 vs 110 minutes), (2) a higher response rate at 40 minutes (56% vs 11%) but lower at day 1 (42% vs 71%), (3) similar remission”
Evidence-based guidelines for treating bipolar disorder: revised third edition Recommendations from the British Association for Psychopharmacology (2009, neutral): “compared paroxetine and bupropion with placebo and the results were certainly negative (Sachs et al., 2007).”
The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders (2013, background): “In a previously described 6-month double-blind placebo-controlled trial (25), rates of mood elevations were indistinguishable (10.”